Is Castle Biosciences Inc (CSTL) overvalued? · rev $344.2M
Castle Biosciences Inc (CSTL) is a diagnostics & research company listed on US.
This page asks whether Castle Biosciences Inc (CSTL) looks expensive on cached numbers — not a short thesis.
Latest reported CSTL revenue for 2025-12-31 was $344.2M. Net income was -$24.2M. Revenue was up 3.7% from 2024-12-31 to 2025-12-31. CSTL currently screens at market cap $570.2M.
CSTL currently screens at market cap $570.2M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CSTL 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CSTL stock page for the full model, not this heading.
Not investment advice.